Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex. The responsibility for developing these products is with our partners.
| Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
|---|
Kisqali® (ribociclib)
CDK4/6 inhibitor (Oncology)
Partner: Novartis
| . | . | . | . | . |
AZD5363 (capivasertib)
PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca
| . | . | . |
JNJ42756493 (erdafitinib)
FGFr inhibitor (Oncology)
Partner: Janssen
| . | . | . |
Multiple Targets and Therapeutic Areas
Partner: GlaxoSmithKline
| . |